A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Phase 1
200
about 2.1 years
18+
3 sites in FL, TN, TX
What this study is about
This trial is testing a treatment called TJ101 for people with advanced solid tumors. The goal is to see if it's safe and effective. Participants will receive TJ101 through IV infusions, have their tumor images checked regularly, provide blood samples, and be monitored for side effects.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take TJ101
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
intravenous
Primary: Number of participants with Serious Adverse Events (SAEs), Number of participants with treatment-emergent adverse events (TEAEs), Number of participants with treatment-related adverse events (TRAEs)
Secondary: Area under the concentration versus time curve (AUC), Clearance (CL), Disease control rate (DCR), Duration of response (DoR), Maximum observed concentration (Cmax), Objective response rate (ORR), Overall survival (OS), Progression-free survival (PFS)
Oncology